Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cash from Financing Activities (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Cash from Financing Activities data on record, last reported at $9.0 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 68.52% year-over-year to $9.0 million; the TTM value through Dec 2025 reached $40.1 million, up 126.8%, while the annual FY2025 figure was $40.1 million, 126.8% up from the prior year.
  • Cash from Financing Activities reached $9.0 million in Q4 2025 per MIRM's latest filing, down from $16.1 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $207.1 million in Q3 2023 and bottomed at -$329000.0 in Q4 2022.
  • Average Cash from Financing Activities over 5 years is $28.8 million, with a median of $6.9 million recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 263548.0% in 2021, then tumbled 153.5% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at $615000.0 in 2021, then crashed by 153.5% to -$329000.0 in 2022, then soared by 640.12% to $1.8 million in 2023, then skyrocketed by 200.51% to $5.3 million in 2024, then surged by 68.52% to $9.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $9.0 million in Q4 2025, $16.1 million in Q3 2025, and $8.7 million in Q2 2025.